CH
RARE icon

Cromwell Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cromwell Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234 Hold
7
– – ﹤0.01% 1088
2026
Q1 		$147 Sell
7
-7
-50% -$158 ﹤0.01% 1032
2025
Q4 		$322 Hold
14
– – ﹤0.01% 991
2025
Q3 		$422 Buy
14
+7
+100% +$210 ﹤0.01% 993
2025
Q2 		$255 Buy
+7
New +$252 ﹤0.01% 998

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Cromwell Holdings's RARE Position: Q2 2026 in Review

Cromwell Holdings held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 7 shares worth $234. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Cromwell Holdings first reported a position in RARE in Q2 2025 and has held it in 5 quarters since. The position peaked at $422 in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Cromwell Holdings held 7 shares of Ultragenyx Pharmaceutical worth $234 as of Q2 2026.
  • Cromwell Holdings left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Cromwell Holdings's portfolio in Q2 2026, its #1088 holding.
  • Cromwell Holdings first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 5 quarters since.
  • Cromwell Holdings's Ultragenyx Pharmaceutical position peaked at $422 in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Cromwell Holdings's 13F filing for Q2 2026, filed 14 Jul 2026.